Biospecific haemosorbents based on proteinase inhibitor. III. Biospecific antiproteinase haemosorbent 'Ovosorb' in complex therapy of acute destructive pancreatitis.

Abstract

Analysis was carried out of the results of complex therapy in 32 patients with acute destructive pancreatitis for which haemosorbtion on Ovosorb, a biospecific antiproteinase haemosorbent containing an immobilized ovomucoid, was used. The clinical efficiency of haemosorbtion was displayed as a decrease in gravity of endogenous intoxication and related functional and metabolic disturbances, as well as in a reduction of lethality from 24.7% to 6.2%.

• Authors: V V Kirkovsky, O F Antiperovich, T A Valueva, V M Moin, G A Lobacheva, O G Berezkina
• Journal: Biomaterials (Biomaterials) Vol. 15 Issue 5 Pg. 334-6 (Apr 1994) ISSN: 0142-9612 [Print] Netherlands
• PMID: 8061123 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Protease Inhibitors
• Ovosorb
• Ovomucin

Topics

• Acute Disease
• Hemoperfusion
• Humans
• Multiple Organ Failure (therapy)
• Ovomucin (therapeutic use)
• Pancreatitis (blood, therapy)
• Protease Inhibitors (metabolism, therapeutic use)